Psykologisk Institut

Genetic risk factors for cancer-related cognitive impairment: a systematic review

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

Standard

Genetic risk factors for cancer-related cognitive impairment : a systematic review. / Buskbjerg, Cecilie D R; Amidi, Ali; Demontis, Ditte; Nissen, Eva R; Zachariae, Robert.

I: Acta Oncologica, Bind 58, Nr. 5, 2019, s. 537-547.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{6e99c7b745184f8494dc7a48003bd16b,
title = "Genetic risk factors for cancer-related cognitive impairment: a systematic review",
abstract = "BACKGROUND: Cancer-related cognitive impairment (CRCI) is a commonly reported complaint among non-CNS cancer patients. Even subtle CRCI may have detrimental effects on quality of life and identifying patients at increased risk for CRCI to improve survivorship care is important. In the present paper, we systematically reviewed available studies of possible genetic risk factors for developing CRCI.METHODS: Keyword-based systematic searches were undertaken on 24 July 2018 in PubMed, Web of Science, The Cochrane Library, and CINAHL. Three authors independently evaluated full-texts of identified papers and excluded studies with registration of reasons. Seventeen studies reporting results from 14 independent samples were included for review. Two authors independently quality assessed the included studies. The review was preregistered with PROSPERO (CRD42018107689).RESULTS: Ten studies investigated apolipoprotein E (APOE), with four studies reporting that carrying at least one risk allele (APOE4 (ε4)) was associated with CRCI, while six studies found no association. The remaining identified genetic risk variants associated with CRCI located in: COMT, four DNA repair genes, five oxidative stress genes, 22 genes related to breast cancer phenotype, and GNB3. No associations were found between CRCI and genes coding for interleukin-6 (IL6), tumor necrosis factor alpha (TNF), interleukin 1 beta (IL1B), and brain-derived neurotropic factor (BDNF). With the exception of APOE, the genetic risk factors had only been investigated in one or two studies each.CONCLUSIONS: Overall, the available evidence of possible genetic risk factors for CRCI is limited. While some research suggests a role for the ε4 allele, the literature is generally inconsistent, and the currently available evidence does not allow clear-cut conclusions regarding the role of genetic factors in the development of CRCI. Larger genetic studies and studies investigating additional genetic variants are needed to uncover genetic risk factors for CRCI.",
keywords = "APOLIPOPROTEIN-E, BREAST-CANCER, CHEMOTHERAPY, COMT, GENOTYPE, MANAGEMENT, MECHANISMS, PERFORMANCE, POLYMORPHISM, THERAPY",
author = "Buskbjerg, {Cecilie D R} and Ali Amidi and Ditte Demontis and Nissen, {Eva R} and Robert Zachariae",
year = "2019",
doi = "10.1080/0284186X.2019.1578410",
language = "English",
volume = "58",
pages = "537--547",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Taylor & Francis ",
number = "5",

}

RIS

TY - JOUR

T1 - Genetic risk factors for cancer-related cognitive impairment

T2 - a systematic review

AU - Buskbjerg, Cecilie D R

AU - Amidi, Ali

AU - Demontis, Ditte

AU - Nissen, Eva R

AU - Zachariae, Robert

PY - 2019

Y1 - 2019

N2 - BACKGROUND: Cancer-related cognitive impairment (CRCI) is a commonly reported complaint among non-CNS cancer patients. Even subtle CRCI may have detrimental effects on quality of life and identifying patients at increased risk for CRCI to improve survivorship care is important. In the present paper, we systematically reviewed available studies of possible genetic risk factors for developing CRCI.METHODS: Keyword-based systematic searches were undertaken on 24 July 2018 in PubMed, Web of Science, The Cochrane Library, and CINAHL. Three authors independently evaluated full-texts of identified papers and excluded studies with registration of reasons. Seventeen studies reporting results from 14 independent samples were included for review. Two authors independently quality assessed the included studies. The review was preregistered with PROSPERO (CRD42018107689).RESULTS: Ten studies investigated apolipoprotein E (APOE), with four studies reporting that carrying at least one risk allele (APOE4 (ε4)) was associated with CRCI, while six studies found no association. The remaining identified genetic risk variants associated with CRCI located in: COMT, four DNA repair genes, five oxidative stress genes, 22 genes related to breast cancer phenotype, and GNB3. No associations were found between CRCI and genes coding for interleukin-6 (IL6), tumor necrosis factor alpha (TNF), interleukin 1 beta (IL1B), and brain-derived neurotropic factor (BDNF). With the exception of APOE, the genetic risk factors had only been investigated in one or two studies each.CONCLUSIONS: Overall, the available evidence of possible genetic risk factors for CRCI is limited. While some research suggests a role for the ε4 allele, the literature is generally inconsistent, and the currently available evidence does not allow clear-cut conclusions regarding the role of genetic factors in the development of CRCI. Larger genetic studies and studies investigating additional genetic variants are needed to uncover genetic risk factors for CRCI.

AB - BACKGROUND: Cancer-related cognitive impairment (CRCI) is a commonly reported complaint among non-CNS cancer patients. Even subtle CRCI may have detrimental effects on quality of life and identifying patients at increased risk for CRCI to improve survivorship care is important. In the present paper, we systematically reviewed available studies of possible genetic risk factors for developing CRCI.METHODS: Keyword-based systematic searches were undertaken on 24 July 2018 in PubMed, Web of Science, The Cochrane Library, and CINAHL. Three authors independently evaluated full-texts of identified papers and excluded studies with registration of reasons. Seventeen studies reporting results from 14 independent samples were included for review. Two authors independently quality assessed the included studies. The review was preregistered with PROSPERO (CRD42018107689).RESULTS: Ten studies investigated apolipoprotein E (APOE), with four studies reporting that carrying at least one risk allele (APOE4 (ε4)) was associated with CRCI, while six studies found no association. The remaining identified genetic risk variants associated with CRCI located in: COMT, four DNA repair genes, five oxidative stress genes, 22 genes related to breast cancer phenotype, and GNB3. No associations were found between CRCI and genes coding for interleukin-6 (IL6), tumor necrosis factor alpha (TNF), interleukin 1 beta (IL1B), and brain-derived neurotropic factor (BDNF). With the exception of APOE, the genetic risk factors had only been investigated in one or two studies each.CONCLUSIONS: Overall, the available evidence of possible genetic risk factors for CRCI is limited. While some research suggests a role for the ε4 allele, the literature is generally inconsistent, and the currently available evidence does not allow clear-cut conclusions regarding the role of genetic factors in the development of CRCI. Larger genetic studies and studies investigating additional genetic variants are needed to uncover genetic risk factors for CRCI.

KW - APOLIPOPROTEIN-E

KW - BREAST-CANCER

KW - CHEMOTHERAPY

KW - COMT

KW - GENOTYPE

KW - MANAGEMENT

KW - MECHANISMS

KW - PERFORMANCE

KW - POLYMORPHISM

KW - THERAPY

UR - http://www.scopus.com/inward/record.url?scp=85066504704&partnerID=8YFLogxK

U2 - 10.1080/0284186X.2019.1578410

DO - 10.1080/0284186X.2019.1578410

M3 - Review

C2 - 30822178

VL - 58

SP - 537

EP - 547

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 5

ER -